Atea is a late-stage clinical biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging Atea’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded RNA viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates.

Atea’s Phase 3 program is evaluating the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir an NS5A inhibitor, for the treatment of hepatitis C virus (HCV). The program consists of two open-label controlled trials, which have collectively enrolled over 1,760 treatment-naïve patients: C-BEYOND in North America and C-FORWARD outside North America. In July 2026, Atea announced positive topline results for C-BEYOND; the trial achieved its primary and secondary endpoints. Topline results from C-FORWARD are anticipated in early Q1 2027. In addition to the HCV program, Atea is advancing a Phase 1 trial for AT-587, a nucleotide analog, for the treatment of hepatitis E virus (HEV).